Enhancing T cell responses to early-stage tumors
Official title: Co-stimulation of T cell responses to nascent, emerging tumors
Funded at University of Pittsburgh at Pittsburgh · NIH-11114661 · Data updated 2026-11-12
This study is looking at how to boost the immune system, especially T cells, to help them spot and fight early-stage tumors before they turn into cancer, and it's for anyone interested in improving cancer prevention.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | March 18, 2025 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $176,712 |
| NIH project number | 1R21CA286410-01A1 |
| Project ID | NIH-11114661 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with a heightened risk of developing cancer, particularly those with known deficiencies in T cell function.
✕Less likely to help
Patients with advanced-stage cancers or those who do not have any known immune deficiencies may not benefit from this research.
What this research studies
This research investigates how the immune system, particularly T cells, can be better activated to recognize and eliminate early-stage tumors before they develop into full-blown cancers. The approach focuses on understanding the mechanisms by which tumor-derived signals can prime T cell responses, utilizing a specific pathway involving heat shock proteins and their interaction with immune cells. By studying these interactions in both mice and humans, the research aims to identify ways to enhance the body's natural defenses against cancer.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for cancer prevention by improving the immune system's ability to detect and destroy nascent tumors.
How similar studies have gone: Previous research has shown promising results in enhancing immune responses to tumors using similar immunological approaches, indicating potential for success in this area.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Binder, Robert J — University of Pittsburgh at Pittsburgh
- Study coordinator: Binder, Robert J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.